Single-ascending doses of MAR002 showed a favourable tolerability and safety profile with no drug-related safety signals ...

The trial achieved its primary endpoint, showing a statistically significant reduction in Valsalva LVOT gradient at week 28.

Bristol-Myers Squibb Company (NYSE:BMY) is one of the cheap S&P 500 stocks to invest in now. On January 12, Bristol-Myers ...

BMS Announces Positive Topline Results from Phase 3 SCOUT-HCM Trial Evaluating Camzyos in Adolescents with Symptomatic oHCM ...

Investors today are cheering envudeucitinib's Phase 3 edge in oral TYK2 psoriasis as well as Alumis' plans to raise fresh ...

Obexelimab met the primary endpoint demonstrating a clinically meaningful and highly statistically significant 56% reduction ...

Johnson & Johnson announced positive topline results from its Phase 2 randomized placebo-controlled JASMINE study. The drug ...

Pfizer Inc. (NYSE:PFE) is one of the most buzzing stocks to invest in according to hedge funds. Earlier on December 17, ...

AnaptysBio, Inc. announced positive Phase 2b trial results for its lead drug, rosnilimab, which targets PD-1+ T cells for rheumatoid arthritis (RA), and will present updated data in June 2025. Initial ...

BiomX reports positive Phase 2 results for BX211 in diabetic foot osteomyelitis and prepares for upcoming Phase 2b trial of BX004. BiomX Inc. announced encouraging topline results from its Phase 2 ...

Company to host conference call and webcast today at 8:00 A.M. ET NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (MTSR), today announced positive topline data from the Phase 1 clinical ...

Interim data from Phase 1 with single and multiple ascending doses show no safety signals and a generally favorable tolerability profile of AGMB-447 in healthy participants -- ...